| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $83,026,619 | 25 | 100 |
| Bodenstedt Matthias | Chief Financial Officer | 0 | $0 | 7 | $3.2M | $-3.2M |
| Reich Kristian | Chief Scientific Officer | 0 | $0 | 10 | $8.14M | $-8.14M |
| Santos da Silva Jorge | Chief Executive Officer | 0 | $0 | 7 | $8.73M | $-8.73M |
| BVF PARTNERS L P/IL | 0 | $0 | 1 | $62.96M | $-62.96M |
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial …
Over the last 12 months, insiders at MoonLake Immunotherapeutics have bought $0 and sold $83.03M worth of MoonLake Immunotherapeutics stock.
On average, over the past 5 years, insiders at MoonLake Immunotherapeutics have bought $36.49M and sold $89.32M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,870 shares for transaction amount of $98,808 was made by Bodenstedt Matthias (Chief Financial Officer) on 2025‑10‑08.
| 2026-07-27 | Sale | Reich Kristian | Chief Scientific Officer | 1,100 0.0013% | $20.00 | $22,000 | -36.49% | |
| 2026-07-22 | Sale | Reich Kristian | Chief Scientific Officer | 2,448 0.0031% | $20.00 | $48,960 | -31.89% | |
| 2026-07-21 | Sale | Reich Kristian | Chief Scientific Officer | 50,000 0.0604% | $20.02 | $1M | -34.99% | |
| 2026-07-20 | Sale | Reich Kristian | Chief Scientific Officer | 43,700 0.0558% | $20.09 | $877,933 | -30.81% | |
| 2026-07-15 | Sale | Reich Kristian | Chief Scientific Officer | 16,105 0.0195% | $20.01 | $322,261 | -32.11% | |
| 2026-07-10 | Sale | Santos da Silva Jorge | Chief Executive Officer | 68,289 0.0912% | $20.02 | $1.37M | -26.62% | |
| 2026-07-09 | Sale | Santos da Silva Jorge | Chief Executive Officer | 33,936 0.0463% | $20.01 | $679,059 | -24.91% | |
| 2026-07-01 | Sale | Santos da Silva Jorge | Chief Executive Officer | 47,775 0.068% | $20.03 | $956,933 | -21.33% | |
| 2026-06-22 | Sale | Bodenstedt Matthias | Chief Financial Officer | 39,120 0.0529% | $22.04 | $862,205 | -31.05% | |
| 2026-06-18 | Sale | Bodenstedt Matthias | Chief Financial Officer | 2,794 0.0039% | $19.60 | $54,762 | -19.99% | |
| 2026-06-17 | Sale | Reich Kristian | Chief Scientific Officer | 50,000 0.0695% | $19.43 | $971,500 | -19.49% | |
| 2026-06-17 | Sale | Bodenstedt Matthias | Chief Financial Officer | 15,082 0.021% | $19.68 | $296,814 | -19.49% | |
| 2026-06-16 | Sale | Reich Kristian | Chief Scientific Officer | 50,000 0.0669% | $18.70 | $935,000 | -18.18% | |
| 2026-06-15 | Sale | Reich Kristian | Chief Scientific Officer | 50,000 0.0669% | $18.89 | $944,500 | -18.99% | |
| 2026-05-11 | Sale | Bodenstedt Matthias | Chief Financial Officer | 13,653 0.0199% | $20.02 | $273,333 | -10.32% | |
| 2026-04-14 | Sale | Bodenstedt Matthias | Chief Financial Officer | 2,426 0.0034% | $19.56 | $47,453 | -8.52% | |
| 2026-04-13 | Sale | Santos da Silva Jorge | Chief Executive Officer | 51,873 0.0679% | $18.23 | $945,645 | -6.73% | |
| 2026-04-10 | Sale | Santos da Silva Jorge | Chief Executive Officer | 98,127 0.1298% | $18.41 | $1.81M | -4.23% | |
| 2026-04-10 | Sale | Bodenstedt Matthias | Chief Financial Officer | 1,925 0.0027% | $19.51 | $37,557 | -4.23% | |
| 2026-04-09 | Sale | Bodenstedt Matthias | Chief Financial Officer | 85,870 0.1328% | $18.94 | $1.63M | -11.33% |
| Bodenstedt Matthias | Chief Financial Officer | 1115435 1.3106% | $13.05M | 1 | 9 | +80.99% |
| Chen Bihua | Former 10% Owner | 1994173 2.3431% | $23.33M | 8 | 2 | <0.0001% |
| Helix Holdings LLC | 430000 0.5052% | $5.03M | 1 | 0 | <0.0001% |
$831,902,292 | 108 | 9.34% | $1.2B | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$5,911,307 | 70 | -1.38% | $884.8M | |
$11,663,618 | 57 | 32.20% | $934.29M | |
$276,808,393 | 17 | -6.69% | $888.11M |
| Increased Positions | 105 | +68.63% | 27M | +71.56% |
| Decreased Positions | 74 | -48.37% | 9M | -22.9% |
| New Positions | 50 | New | 14M | New |
| Sold Out Positions | 50 | Sold Out | 7M | Sold Out |
| Total Postitions | 184 | +20.26% | 56M | +48.66% |
| Bvf Inc/Il | $236,028.00 | 27.82% | 19.75M | 0 | 0% | 2025-09-30 |
| Avoro Capital Advisors Llc | $23,900.00 | 2.82% | 2M | -2M | -51.81% | 2025-09-30 |
| Cormorant Asset Management, Lp | $23,830.00 | 2.81% | 1.99M | -6M | -76.52% | 2025-09-30 |
| Balyasny Asset Management L.P. | $20,306.00 | 2.39% | 1.7M | +1M | +301.55% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $17,925.00 | 2.11% | 1.5M | +2M | New | 2025-09-30 |
| Schonfeld Strategic Advisors Llc | $11,537.00 | 1.36% | 965,405 | +965,405 | New | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $9,834.00 | 1.16% | 822,957 | -2M | -68.51% | 2025-09-30 |
| Fmr Llc | $8,687.00 | 1.02% | 726,932 | -5M | -87.31% | 2025-09-30 |
| Nuveen, Llc | $7,597.00 | 0.9% | 635,699 | -155,856 | -19.69% | 2025-09-30 |
| Two Sigma Investments, Lp | $5,429.00 | 0.64% | 454,268 | +454,268 | New | 2025-09-30 |